February 24, 2021 -- ERS Genomics has signed a nonexclusive licensing deal granting G+FLAS Life Sciences access to its CRISPR/Cas9 patent portfolio.
G+FLAS is applying CRISPR technology to the development of drugs and production of CRISPR genome edited plants in a non-GMO way. These products include plant-based trastuzumab, a biosimilar antibody, and a cas9 monoclonal antibody to be used to test the development of Cas9-based gene therapy products.
ERS Genomics holds the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier.